Dr Philip Molyneaux is a Clinical Senior Lecturer in Interstitial lung disease and an Honorary Consultant at the Royal Brompton Hospital.
Philip qualified from Guy's, King's and St Thomas' School of Medicine in 2004, where he completed an intercalated BSc. in Molecular Genetics. He undertook his SHO training at Guy’s and St Thomas’ and upon completion of the MRCP attained an NIHR Academic Clinical Fellow position in Respiratory medicine at Imperial College. He spent the next two years training at St Mary’s Hospital and working with Professors Cookson, Moffatt and Johnston studying the respiratory microbiome in COPD.
An Asmarley training fellowship allowed him to undertake a PhD examining the host response to the respiratory microbiome in Idiopathic Pulmonary Fibrosis as part of the Prospective Study of Fibrosis In the Lung Endpoints (PROFILE) study with Professors Maher, Cookson and Moffatt.
Having completed his clinical training in Respiratory and Critical Care Medicine he returned to Imperial joining the Fibrosis Research Group as a Senior Clinical Lecturer. He also holds a position as Consultant in Interstitial Lung Disease at the Royal Brompton Hospital where he has a special interest in Familial Pulmonary Fibrosis.
et al., 2020, Presence of pleomorphic features but not growth patterns improves prognostic stratification of epithelioid malignant pleural mesothelioma by 2-tier nuclear grade., Histopathology, ISSN:0309-0167
et al., 2020, Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent, European Respiratory Journal, Vol:55, ISSN:0903-1936, Pages:1-9
et al., 2020, Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease, Clinical Rheumatology, Vol:39, ISSN:0770-3198, Pages:1173-1179
et al., 2020, A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor, Respiratory Research, Vol:21, ISSN:1465-9921
Invernizzi R, Lloyd CM, Molyneaux PL, 2020, Respiratory microbiome and epithelial interactions shape immunity in the lungs., Immunology, ISSN:0019-2805